BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

391 related articles for article (PubMed ID: 25603726)

  • 1. Asparaginase Therapy in Pediatric Acute Lymphoblastic Leukemia: A Focus on the Mode of Drug Resistance.
    Chen SH
    Pediatr Neonatol; 2015 Oct; 56(5):287-93. PubMed ID: 25603726
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Asparaginase in acute lymphoblastic leukemia.
    Kawedia JD; Rytting ME
    Clin Lymphoma Myeloma Leuk; 2014 Sep; 14 Suppl():S14-7. PubMed ID: 25486949
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Asparaginase Toxicities: Identification and Management in Patients With Acute Lymphoblastic Leukemia
.
    Thu Huynh V; Bergeron S
    Clin J Oncol Nurs; 2017 Oct; 21(5):E248-E259. PubMed ID: 28945721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FDA drug approval summary: pegaspargase (oncaspar) for the first-line treatment of children with acute lymphoblastic leukemia (ALL).
    Dinndorf PA; Gootenberg J; Cohen MH; Keegan P; Pazdur R
    Oncologist; 2007 Aug; 12(8):991-8. PubMed ID: 17766659
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Up-regulation of asparagine synthetase expression is not linked to the clinical response L-asparaginase in pediatric acute lymphoblastic leukemia.
    Appel IM; den Boer ML; Meijerink JP; Veerman AJ; Reniers NC; Pieters R
    Blood; 2006 Jun; 107(11):4244-9. PubMed ID: 16497975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. No evidence of increased asparagine levels in the bone marrow of patients with acute lymphoblastic leukemia during asparaginase therapy.
    Tong WH; Pieters R; Hop WC; Lanvers-Kaminsky C; Boos J; van der Sluis IM
    Pediatr Blood Cancer; 2013 Feb; 60(2):258-61. PubMed ID: 22961784
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of recombinant E. coli asparaginase in children with previously untreated acute lymphoblastic leukemia: A randomized multicenter study of the Dutch Childhood Oncology Group.
    van der Sluis IM; de Groot-Kruseman H; Te Loo M; Tissing WJE; van den Bos C; Kaspers GJL; Bierings M; Kollen WJW; König T; Pichlmeier U; Kühnel HJ; Pieters R
    Pediatr Blood Cancer; 2018 Aug; 65(8):e27083. PubMed ID: 29727043
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TropicALL study: Thromboprophylaxis in Children treated for Acute Lymphoblastic Leukemia with Low-molecular-weight heparin: a multicenter randomized controlled trial.
    Klaassen ILM; Lauw MN; van de Wetering MD; Biemond BJ; Middeldorp S; Abbink FCH; Bierings M; Te Loo DMMW; Pieters R; van der Sluis IM; Tissing WJE; Michel Zwaan C; Heleen van Ommen C
    BMC Pediatr; 2017 May; 17(1):122. PubMed ID: 28486976
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of L-asparaginase in childhood ALL.
    Müller HJ; Boos J
    Crit Rev Oncol Hematol; 1998 Aug; 28(2):97-113. PubMed ID: 9768345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Asparaginase pharmacokinetics after intensive polyethylene glycol-conjugated L-asparaginase therapy for children with relapsed acute lymphoblastic leukemia.
    Hawkins DS; Park JR; Thomson BG; Felgenhauer JL; Holcenberg JS; Panosyan EH; Avramis VI
    Clin Cancer Res; 2004 Aug; 10(16):5335-41. PubMed ID: 15328169
    [TBL] [Abstract][Full Text] [Related]  

  • 11. L-asparaginase (Leunase) induced pancreatitis in childhood acute lymphoblastic leukemia.
    Sahu S; Saika S; Pai SK; Advani SH
    Pediatr Hematol Oncol; 1998; 15(6):533-8. PubMed ID: 9842647
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cerebrospinal fluid asparagine depletion during pegylated asparaginase therapy in children with acute lymphoblastic leukaemia.
    Henriksen LT; Nersting J; Raja RA; Frandsen TL; Rosthøj S; Schrøder H; Albertsen BK;
    Br J Haematol; 2014 Jul; 166(2):213-20. PubMed ID: 24702187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mesenchymal cells regulate the response of acute lymphoblastic leukemia cells to asparaginase.
    Iwamoto S; Mihara K; Downing JR; Pui CH; Campana D
    J Clin Invest; 2007 Apr; 117(4):1049-57. PubMed ID: 17380207
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peg-asparaginase for acute lymphoblastic leukemia.
    Rytting M
    Expert Opin Biol Ther; 2010 May; 10(5):833-9. PubMed ID: 20345338
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How to manage asparaginase hypersensitivity in acute lymphoblastic leukemia.
    Burke MJ
    Future Oncol; 2014 Dec; 10(16):2615-27. PubMed ID: 24983955
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activity and Toxicity of Intravenous Erwinia Asparaginase Following Allergy to E. coli-Derived Asparaginase in Children and Adolescents With Acute Lymphoblastic Leukemia.
    Vrooman LM; Kirov II; Dreyer ZE; Kelly M; Hijiya N; Brown P; Drachtman RA; Messinger YH; Ritchey AK; Hale GA; Maloney K; Lu Y; Plourde PV; Silverman LB
    Pediatr Blood Cancer; 2016 Feb; 63(2):228-33. PubMed ID: 26376459
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Desensitization to pegaspargase in children with acute lymphoblastic leukemia and lymphoblastic lymphoma.
    August KJ; Farooki S; Fulbright JM; August A; Portnoy JM; Pommert L; Burke MJ; Guest EM
    Pediatr Blood Cancer; 2020 Jan; 67(1):e28021. PubMed ID: 31571395
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Asparaginase-associated pancreatitis in children with acute lymphoblastic leukaemia in the NOPHO ALL2008 protocol.
    Raja RA; Schmiegelow K; Albertsen BK; Prunsild K; Zeller B; Vaitkeviciene G; Abrahamsson J; Heyman M; Taskinen M; Harila-Saari A; Kanerva J; Frandsen TL;
    Br J Haematol; 2014 Apr; 165(1):126-33. PubMed ID: 24428625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma asparaginase activity, asparagine concentration, and toxicity after administration of Erwinia asparaginase in children and young adults with acute lymphoblastic leukemia: Phase I/II clinical trial in Japan.
    Ogawa C; Taguchi F; Goto H; Koh K; Tomizawa D; Ohara A; Manabe A
    Pediatr Blood Cancer; 2017 Sep; 64(9):. PubMed ID: 28244643
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with L-asparaginase: results of the Prophylactic Antithrombin Replacement in Kids with Acute Lymphoblastic Leukemia Treated with Asparaginase (PARKAA) Study.
    Mitchell LG; Andrew M; Hanna K; Abshire T; Halton J; Anderson R; Cherrick I; Desai S; Mahoney D; McCuster P; Wu J; Dahl G; Chait P; de Veber G; Lee KJ; Mikulis D; Ginsberg J; Way C;
    Cancer; 2003 Jan; 97(2):508-16. PubMed ID: 12518376
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.